Five patients with 45,X/46,XY mosaicism ranging from 8% to 66% of 46,XY lymphocytes in the peripheral blood were studied. Their age when chromosome studies were performed ranged from a few days to 37 yr. The phenotypic presentations were two females with gonadal dysgenesis and Turner syndrome features (cases 1 and 2), two males with ambiguous genitalia and mixed gonadal dysgenesis (cases 3 and 4), and an infertile male with an atrophic testis (case 5). Fluorescence in situ hybridization (FISH) using dual-color X and Y probes on paraffin-embedded sections of the gonads was performed to assess mosaicism. A mosaic cell line with a Y chromosome was present in the streak ovary, dysgenetic gonad, and testis. In the mixed gonadal dysgenesis cases (cases 3 and 4), the testis had a higher percentage (greater than two fold) of XY cells than the ovary had. However, the highest ratio of cells with a Y chromosome was in the atrophic testis of the infertile male (case 5). The distribution of mosaic clones in the different gonadal cell types was examined. Both females (cases 1 and 2) with dysgenetic gonads had scant ovarian stroma and nests of Leydig or hilus cells. In FISH studies, the coelomic epithelial cells were predominantly 46,XY; in comparison, the Leydig and hilus cells had a lower percentage and the ovarian stroma the least number of cells with a Y signal. A mixed gonadal dysgenesis case (case 3) possessed a right testis with an XY complement in ∼21% of Sertoli cells and ∼14% of Leydig cells. The infertile male had an atrophic testis with interstitial hyperplasia (case 5). His testis contained Sertoli cells but no evidence of spermatogenesis. FISH detected a Y signal in about 50–60% of the Sertoli and Leydig cells.

1.
Capel B, Lovell-Badge R: The SRY gene and sex determination in mammals. Adv dev Biol 2:1–35 (1993).
2.
De Silva MS, Hacker A, Harley V, Goodfellow P, Swain A, Lovell-Badge R: Sox9 expression during gonadal development implies a conserved role for the gene in testis differentiation in mammals and birds. Nature Genet 14:62–68 (1996).
3.
Gubbay J, Collingnon J, Koopman P, Capel B, Economou A, Munsterberg A, Vivian N, Goodfellow P, Lovell-Badge R: A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes. Nature 346:245–250 (1990).
4.
Jeske YWA, Bowles J, Greenfield A, Koopman P: Expression of a linear Sry transcript in the mouse genital ridge. Nat Genet. 10:480–482 (1995).
5.
Jost A, Vigier B, Prepin J, Perchellet J: Studies on sex differentiation in mammals. Rec Prog Horm Res 29:1–41 (1973).
6.
Kent J, Wheatley SC, Andrews JE, Sinclair AH, Koopman P: A male-specific role for Sox9 in vertebrate sex determination. Development 122:2813–2822 (1996).
7.
Mittwoch U: Males, females and hermaphrodites. Ann hum Genet 50:103–121 (1985).
8.
Mittwoch U, Kirk D: Superior growth of the right testis in human fetuses. Nature 257:791–792 (1975).
9.
Mittwoch U, Mahadevaiah S: Additional growth—a link between mammalian testis, avian ovaries, gonadal asymmetry in hermaphrodites and the expression of H-Y antigen. Growth 44:287–300 (1980).
10.
Palmer SJ, Burgoyne PS: In situ analysis of fetal, prepubertal and adult XX↔1XY chimeric mouse testes: Sertoli cells are predominantly, but not exclusively, XY. Development 112:265–268 (1991).
11.
Patek CE, Kerr J, Gosden R, Jones KW, Hardy K, Muggleton-Harris A, Handyside A, Whittingham D, Hooper ML: Sex chimerism, fertility and sex determination in the mouse. Development 113:311–325 (1991).
12.
Ragg S, Harle M, Scherthan H: Analysis of sex chromosome distribution in the gonadal tissue of a 45,X/47,XYY mosaic by fluorescence in situ hybridization. Mod Path 8:295–298 (1995).
13.
Reddy KS, Sulcova V, Ho CK, Conner ED, Khurana A: An infant with a mosaic 45,X/46,X,psu dic(Y)(pter→q11.2::q11.2→pter) karyotype and mixed gonadal dysgenesis studied for the extent of mosaicism in the gonads. Am J med Genet 66:441–444 (1996).
14.
Rosenberg C, Frota-Pessoa O, Vianna-Morgante AM, Chu TH: Phenotypic spectrum of 45,X/46,XY individuals. Am J med Genet 27:553 (1987).
15.
Schafer AJ: Sex determination and its pathology in man. Adv Genet 33:275–329 (1995).
16.
Schafer AJ, Goodfellow PN: Sex determination in humans. Bioessays 18:955–963 (1996).
17.
Simpson JL: Abnormal sex differentiation in humans. Ann Rev Genet 16:193 (1982)
18.
Sinclair AH, Betta P, Palmer MS, Hawkins JR, Griffiths BL, Smith MJ, Foster JW, Frischauf AM, Lovell-Badge R, Goodfellow PN: A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif. Nature 346:240–244 (1990).
19.
Singh K.D, Matsukuma S, Jones KW: Testis development in a mouse with 10% of XY cells. Dev Biol 122:287 (1987).
20.
Swain A, Narvaez V, Burgoyne P, Camerino G, Lovell-Badge R, Dax1 antagonizes Sry action in mammalian sex determination. Nature 391:761–767 (1988).
21.
van Niekirk WA, Retief AE: The gonads of human true hermaphrodites. Hum Genet 58:117–122 (1981).
22.
Verma R, Babu A: Human Chromosomes: Manual of Basic Techniques, pp 47–50 (Pergamon Press, London/New York 1989).
23.
Verp MS, Simpson IL: Abnormal sexual differentiation and neoplasia. Cancer Genet Cytogenet 25:191–218 (1987).
24.
Wylie CC, Heasman J: Migration, proliferation and potency of primordial germ cells. Sem devl Biol 4:161–170 (1993).
25.
Yunis J: High resolution banding of human chromosomes. Science 191:1268–1270 (1976).
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.